• by developer
• (0) Comments

Bajaj Healthcare Soars to Record High

Bajaj Healthcare Hits Record High on Exclusive Rights for Magtein in India.

Bajaj Healthcare’s stock surged 13.41% to ₹637.25 after the company announced that it has secured exclusive rights to manufacture, distribute, and sell the finished formulation of Magnesium L-Threonate (Magtein) in India. This milestone agreement has been established with Threotech LLC.

Under the agreement, Bajaj Healthcare will have rights to:

• Manufacture, market, and distribute Magtein in India.
• Co-market the product to further expand its reach.

Bajaj Healthcare has already been supplying the API for Magnesium L-Threonate (Magtein) to Threotech LLC in the United States. The Magtein brand, owned by Threotech LLC, has a sales value of approximately $438 million globally.

Anil Jain, Managing Director of Bajaj Healthcare, shared: “Our collaboration with Threotech LLC has reached an exciting milestone with the licensing rights for Magtein in India. With our strong domestic presence and proven expertise in manufacturing and distribution, we are well-positioned to unlock the product’s full potential in the Indian market. This partnership reaffirms our role as a trusted partner for international clients and showcases our ability to integrate manufacturing excellence with strategic market outreach.”

This development marks a significant step for Bajaj Healthcare in strengthening its portfolio and expanding its presence in the Indian healthcare market.

Bajaj Healthcare Achieves All-Time High Amid Robust Financial Growth

Bajaj Healthcare, a prominent manufacturer of APIs, intermediates, and formulations, continues to strengthen its global footprint across regions like Europe, the USA, Australia, Africa, the Middle East, and South America.

The company reported impressive financial results for Q2 FY25, highlighting its strong performance:

• Net Profit: ₹94.64 crore, a remarkable turnaround from a net loss of ₹34.60 crore in Q2 FY24.
• Revenue from Operations: ₹133.08 crore, reflecting a 31.5% YoY growth.

The company’s stock hit an all-time high of ₹655 intraday, driven by investor confidence and robust growth prospects.

This milestone underscores Bajaj Healthcare’s commitment to delivering excellence in the pharmaceutical industry, both in India and globally.

News Source: https://www.business-standard.com/markets/capital-market-news/bajaj-healthcare-hits-record-high-after-receiving-rights-to-manufacture-magtein-in-india-125011700417_1.html

Disclaimer: The information provided in this newsletter is for general informational purposes only and reflects the latest updates and trends across various sectors. While we strive for accuracy, Aristocrat Media assumes no responsibility for errors or omissions. Readers are encouraged to verify details independently and consult appropriate professionals before making decisions.

💡 Stay Connected: Don’t miss out on our updates! Subscribe to our channel and follow us on LinkedIn, YouTube, and Instagram for more insights and exclusive content.

🌟 Your feedback matters! If you have suggestions or topics you’d like us to cover, feel free to reach out.

Email – info@aristocrat-media.com

#FinancialGrowth #PharmaExcellence #BajajHealthcare #GlobalReach